Even if microbiota-relateds treatments are quite recent in the therapeutical field, at least 2,400 clinical trials were launched in 2018! Gut, skin and oncology microbiota will be definitively be the hot topic in the next 10 years. Of course, we are heavily working in the field, with a focus on skin with the reconstruction of a 3D “in vitro” skin model with BIOMIMESYS® in a HCS context.

Gut Microbiota from https://labiotech.eu

As explained in this article, an important step will be also the adaptation of EU drug regulation to make the commercialization of such treatments easier.

The companies will propose EU regulatory changes that make it easier to commercialize treatments based on targeting a patient’s microbiome bacteria. Microbiome-based treatments form a young field in the industry, with big potential to treat diseases such as inflammatory bowel disease and even cancer.

Source: Microbiome Companies Unite to Push for EU Regulation Reform


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

Leave a Reply